GANX News and Press, Gain Therapeutics Inc. From 08/28/23

Treatment with GT-02287 also restored glucocerebrosidase (GCase) enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and improved motor function Data presented at the International Congress of Parkinson's Disease a...

2023-08-14 05:45:30 ET Summary Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, including ALS. Coya Therapeutics' ALS drug could be approved based on pivotal phase 2 results and could po...

2023-08-10 10:31:02 ET Gain Therapeutics press release ( NASDAQ: GANX ): Q2 GAAP EPS of -$0.62. Cash, cash equivalents and marketable securities were $16.2 million as of June 30, 2023, For further details see: Gain Therapeutics GAAP EPS of -$0.62

HREC application submitted; on track to initiate Phase 1 clinical study of GT-02287 this year Acceptance of late breaking abstract for presentation at the International Congress of Parkinson’s Disease and Movement Disorders ® in Copenhagen, Denmark BETHESDA...

BETHESDA, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a late breaking abstract highlighting the company’s le...

BETHESDA, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that members of management will par...

BETHESDA, Md., June 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executiv...

2023-05-31 05:55:18 ET Summary Gain Therapeutics is a biotechnology company focused on drug development powered by its SEE-Tx™ target identification platform, which identifies and optimizes binding sites on biological targets that have never before been targeted. The compan...

2023-05-12 09:06:27 ET Gain Therapeutics press release ( NASDAQ: GANX ): Q1 GAAP EPS of -$0.43. Revenue of $0.06M (+20.0% Y/Y). Cash, cash equivalents and marketable securities were $18.8 million as of March 31, 2023. The Company believes that this amount, together...

Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s disease Company is on track to submit application for start of Phase 1 clinical trial of GT-02287 to the Human Research Ethics Committee (HREC) in Australia in mid-2023 Received a $2...